ISRCTN48523317已完成不适用
Recombinant human erythropoietin therapy in critically ill patients: a dose response study
Janssen-Cilag (Greece)0 个研究点目标入组 148 人开始时间: 2005年6月16日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 148
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •All patients admitted to the intensive care unit (ICU) in each of the 13 participating centres were evaluated for study eligibility. Inclusion criteria were:
- •1. Age at least 18 years
- •2. Hb less than 12 g/dl
- •3. No iron deficiency defined as transferrin saturation less than 10% and ferritin less than 50 ng/ml
- •4. Negative pregnancy test (for females in the reproductive age)
- •5. An expected ICU stay of at least 7 days
- •6. Provision of signed informed consent
- •The expected duration of the ICU stay was judged on clinical grounds and APACHE II score by the ICU team at admittance to the unit.
排除标准
- •1. Chronic renal failure requiring dialysis
- •2. New onset (less than 6 months) seizures
- •3. Life expectancy of less than 7 days
- •4. Previous use of rHuEPO (within 3 months)
- •5. Recent use of cytostatics or recent radiotherapy (within 1 month)
- •6. Participation in another research protocol
研究者
相似试验
已完成
1 期
The benefits of Erythropoietin in reducing the need for blood transfusions in patients receiving chemotherapysolid insitu tumor of the body.In situ neoplasmsD00-D09IRCT2015061822805N1Vice Chancellor for research of Tabriz University of Medical Sciences60
尚未招募
不适用
Effect of recombinant human erythropoietin administration before cardiopulmonary bypass on the development of postoperative acute kidney injury in patients undergoing valvular heart surgeryDiseases of the circulatory systemKCT0000696Asan Medical Center228
已完成
4 期
Impact of Recombinant Human Erythropoietin (ior EPO-CIM) in oncology pediatric patients with post chemo and /or radiotherapy.Anemia secondary to chemo and/or radiotherapy.RPCEC00000080Center of Molecular Immunology(CIM)161
尚未招募
3 期
Erythropoietin for Perinatal asphyxiaCTRI/2018/04/013331Dr Atul Londhe
已完成
4 期
Impact of Human Recombinant Erithoropoietin (ior EPOCIM) in cancer patients with post Chemo and Radiotherapy induced anemia.Anemia secondary to chemo and/or radiotherapy.RPCEC00000079Center of Molecular Immunology(CIM)338